Personalized medicine company developing biomarkers to stratify breast cancer population and predict bone metastasis.

Founded in 2010 in Barcelona, as a spin off from the Barcelona Institute for Biomedical Research.
It has developed a personalized biomarker for early-stage breast cancer. The company’s diagnostic assay has the potential to identify early-stage breast cancer patients who will benefit from bisphosphonate adjuvant treatment with the aim to improve their overall and disease-free survival while excluding patients who will not benefit or can be harmed.